Anemia and Other Blood Disorder Drugs Global Market Report 2023: Market Set to Grow to $14.80 billion in 2027 at a CAGR of 5.7%

DUBLIN, March 1, 2023 /PRNewswire/ -- The "Anemia And Other Blood Disorder Drugs Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering.

The global anemia and other blood disorder drugs market is forecast to grow from $11.14 billion in 2022 to $11.87 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%.

The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The anemia and other blood disorder drugs market is expected to grow to $14.80 billion in 2027 at a CAGR of 5.7%.

North America is the largest region in the anemia and other blood disorder drugs market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia is a common kind of anemia in which the blood does not contain enough healthy red blood cells. The oxygen-carrying red blood cells transport oxygen to the body's cells. The different types of anemia include microcytic (Low MCV), normocytic (Normal MCV), and macrocytic (High MCV) and involve various routes of administration such as oral, and injectable. It is distributed through hospitals pharmacies, online pharmacies, and pharmacy.

The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. the World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the market.

There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids, or a combination of these substances or might be derived from living organisms like humans, animals, or microorganisms or that may contain components of living organisms. The growth in the use of biologics over the drugs restricts the market resulting in the decline of the number of drugs being used for the treatment of anemia& other blood disorders. For example, Hospira, a medical device and pharmaceutical company, submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, the FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The increase in the use of biologics will hamper the growth of the market.

Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology, and cost. Such collaborations are also helpful to the companies in case of expiring licenses and a stringent regulatory environment. For example, in 2020, Akebia Therapeutics announced collaboration with Tobacco Inc to treat adult patients with iron deficiency anemia. Another such example is, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. agreed to manufacture and commercialize vadadustat, an oral HIF stabilizer, used for the treatment of anemia.

The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get its drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark.

In October 2022, Pfizer, a US-based pharmaceutical company acquired Global Blood Therapeutics Inc. for an undisclosed amount. Through this acquisition, Pfizer expanded its portfolio in the development of drugs and brought various potential best-in-class treatments to people living with sickle cell disease. Global Blood Therapeutics Inc is a US-based biotech company operating in anemia and other blood disorder drugs.

The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Report Scope

Markets Covered:

1) By Type: Iron Deficiency Anemia; Chronic Kidney Disease Anemia; Sickle Cell Anemia; Aplastic Anemia
2) By Distribution Channel: Hospitals Pharmacy; Online Pharmacy; Pharmacy
3) By Route of Administration: Oral; Injectable
4) By Anemia Type: Microcytic (Low MCV); Normocytic (Normal MCV); Macrocytic (High MCV)

Companies Mentioned: Amgen Inc.; GlaxoSmithKline plc; Akebia therapeutics ; Bayer AG ; Pfizer

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.


Key Topics Covered:

1. Executive Summary

2. Anemia And Other Blood Disorder Drugs Market Characteristics

3. Anemia And Other Blood Disorder Drugs Market Trends And Strategies

4. Anemia And Other Blood Disorder Drugs Market - Macro Economic Scenario
4.1 COVID-19 Impact On Anemia And Other Blood Disorder Drugs Market
4.2 Ukraine-Russia War Impact On Anemia And Other Blood Disorder Drugs Market
4.3 Impact Of High Inflation On Anemia And Other Blood Disorder Drugs Market

5. Anemia And Other Blood Disorder Drugs Market Size And Growth
5.1. Global Anemia And Other Blood Disorder Drugs Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Anemia And Other Blood Disorder Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Anemia And Other Blood Disorder Drugs Market Segmentation
6.1. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Iron Deficiency Anemia
• Chronic Kidney Disease Anemia
• Sickle Cell Anemia
• Aplastic Anemia

6.2. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Hospitals Pharmacy
• Online Pharmacy
• Pharmacy

6.3. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Oral
• Injectable

6.4. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Anemia Type , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Microcytic (Low MCV)
• Normocytic (Normal MCV)
• Macrocytic (High MCV)

7. Anemia And Other Blood Disorder Drugs Market Regional And Country Analysis
7.1. Global Anemia And Other Blood Disorder Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Anemia And Other Blood Disorder Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8-26. Region Breakdowns for Anemia And Other Blood Disorder Drugs Market


27. Anemia And Other Blood Disorder Drugs Market Competitive Landscape And Company Profiles
27.1. Anemia And Other Blood Disorder Drugs Market Competitive Landscape
27.2. Anemia And Other Blood Disorder Drugs Market Company Profiles
27.2.1. Amgen Inc.
27.2.2. GlaxoSmithKline plc
27.2.3. Akebia therapeutics
27.2.4. Bayer AG
27.2.5. Pfizer, Inc.

28. Anemia And Other Blood Disorder Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Anemia And Other Blood Disorder Drugs Market

30. Anemia And Other Blood Disorder Drugs Market Future Outlook and Potential Analysis

For more information about this report visit https://www.researchandmarkets.com/r/941lrt-other?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets